OP35The role of induction therapy before autologous stem cell transplantation in AL amyloidosis patients with bone marrow plasma cells less than 10%
Xianghua Huang, Jiangsu, China
OP36Ixazomib-dexamethasone versus physician’s choice in relapsed/refractory systemic al amyloidosis: Results from the phase 3 tourmaline-al1 trial
Giampaolo Merlini, Pavia, Italy
OP37Subcutaneous daratumumab + cyclophosphamide/bortezomib/dexamethasone in newly diagnosed al amyloidosis: Updated safety run-in results of andromeda
Raymond L. Comenzo, Boston, MA, USA
OP38Assessment of minimal residual disease using multiparametric flow cytometry in treated patients with al amyloidosis
Andrew Staron, Boston, MA, USA
OP39One-year evaluation of the incidence and distribution of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry
Ute Hegenbart, Heidelberg, Germany
OP40Localised laryngeal amyloid – A series of 100 cases
Helen Lachmann, London, UK
Giampaolo Merlini, Pavia, Italy
Stefan Schönland, Heidelberg, Germany
Vaishali Sanchorawala, Boston, MA, USA
Arnaud Jaccard, Limoges, France
Bouke Hazenberg, Groningen, The Netherlands
Bruno Paiva, Pamplona, Spain
Rámon Lecumberri, Pamplona, Spain
• When to suspect AL amyloidosis during MGUS follow-up?
• New response criteria needed?
• Is there a role for MRD assessment?
• Are we curing AL amyloidosis in 2020?
• Amyloid deposition in organ transplant recipients?
Matthias Schmidt, Ulm, Germany
Ole Suhr, Umeå, Sweden
Violaine Plante-Bordeneuve, Créteil, France
Esther González-López, Madrid, Spain
Joel Buxbaum, La Jolla, CA, USA
Juan Buades, Palma de Mallorca, Spain
• What is the real prevalence of wild type ATTR amyloidosis?
• What are the critical endpoints in ATTR polyneuropathy?
• Best treatment approach at lack of response to patisiran or inotersen?
• Is it time for combination therapy trials?
• What is the best approach to ATTR mutant carriers?
Clinical Trials in Progress in Systemic Amyloidosis